Quantification of Alzheimer pathology in ageing and dementia: age‐related accumulation of amyloid‐β(42) peptide in vascular dementia
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Clinicopathological observations suggest there is considerable overlap between vascular dementia (VaD) and Alzheimer's disease (AD). We used immunochemical methods to compare quantities of amyloid‐β (Aβ) peptides in post mortem brain samples from VaD, AD subjects and nondemented ageing controls. Total Aβ peptides extracted from temporal and frontal cortices were quantified using a previously characterized sensitive homogenous time‐resolved fluorescence (HTRF) assay. The HTRF assays and immunocapture mass spectrometric analyses revealed that the Aβ(42) species were by far the predominant form of extractable peptide compared with Aβ(40) peptide in VaD brains. The strong signal intensity for the peak representing Aβ(4–42) peptide confirmed that these N‐terminally truncated species are relatively abundant. Absolute quantification by HTRF assay showed that the mean amount of total Aβ(42) recovered from VaD samples was approximately 50% of that in AD, and twice that in the age‐matched controls. Linear correlation analysis further revealed an increased accumulation with age of both Aβ peptides in brains of VaD subjects and controls. Interestingly, VaD patients surviving beyond 80 years of age exhibited comparable Aβ(42) concentrations with those in AD in the temporal cortex. Our findings suggest that brain Aβ accumulates increasingly with age in VaD subjects more so than in elderly without cerebrovascular disease and support the notion that they acquire Alzheimer‐like pathology in older age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
(2001) · The Lancet · doi:10.1016/s0140-6736(00)03589-3 · Cited by 1,338
Cited by
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Self-citationThe overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739
“It was also suggested that more Aβ accumulates with age in brains of vascular dementia (VaD) subjects compared to elderly without CVD [66].”
BackgroundThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
“Indeed, brain Ab levels and amyloid plaques are elevated in patients with cerebrovascular insufficiency and VCI [68].”
Degorce, F. (2009) · Current Chemical Genomics · doi:10.2174/1875397300903010022 · Cited by 501
“age-matched controls, researchers were able to identify a link between the presence of these proteins and vascular dementia [74].”
BackgroundBurton, E. J., Barber, R., Mukaetova-Ladinska, E. B., Robson, J., Perry, R. H., Jaros, E., Kalaria, R. N., & O’Brien, J. T. (2009) · Brain · doi:10.1093/brain/awn298 · Cited by 370
Self-citationPathology and pathogenesis of vascular cognitive impairment—a critical update
Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
Kalaria, R. N. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00352.x · Cited by 290
Self-citationIhara, M., Polvikoski, T. M., Hall, R., Slade, J. Y., Perry, R. H., Oakley, A. E., Englund, E., O’Brien, J. T., Ince, P. G., & Kalaria, R. N. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0635-8 · Cited by 244
“As previously described [30], the neuropathological diagnoses of VaD [28], AD [9, 37], and DLB [35] were made by thorough histopathological examination of extensively sampled brain sections.”
BackgroundSelf-citationAllan, L. M., Rowan, E. N., Firbank, M. J., Thomas, A. J., Parry, S. W., Polvikoski, T. M., O'Brien, J. T., & Kalaria, R. N. (2011) · Brain · doi:10.1093/brain/awr273 · Cited by 225
“While stroke survivors may not be completely free of Alzheimer pathology or amyloid-b accumulation (Lewis et al., 2006; Mok et al., 2010), these data indicated that elderly stroke survivors, at least in the 475 age group, are likely to develop vascular dementia with minimal Alzheimer’s disease…”
BackgroundSelf-citationPyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease
Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 218
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1129-2 · Cited by 175
Morphologic diagnosis of “vascular dementia” — A critical update
Jellinger, K. A. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.03.006 · Cited by 150
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802328142 · Cited by 147
“Based upon the study of Lewis et al.5, it was considered that younger patients (575 years) might be less likely to have concomitant AD pathology24.”
Self-citationBanik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Self-citationFrontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old
Polvikoski, T. M., van Straaten, E. C. W., Barkhof, F., Sulkava, R., Aronen, H. J., Niinistö, L., Oinas, M., Scheltens, P., Erkinjuntti, T., & Kalaria, R. N. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d6f9 · Cited by 88
Self-citationWalter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1929-5 · Cited by 65
Self-citationAlzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17338 · Cited by 61
Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53
“[22] reported that Aβ4-42 is a relatively abundant species in AD, aged controls and vascular dementia patients.”
BackgroundElbert, D. L., Patterson, B. W., Lucey, B. P., Benzinger, T. L. S., & Bateman, R. J. (2022) · Communications Biology · doi:10.1038/s42003-022-03037-0 · Cited by 53
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia
Burton, E. J., Mukaetova-Ladinska, E. B., Perry, R. H., Jaros, E., Barber, R., & O'Brien, J. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.015 · Cited by 43
“Standard immunohistochemistry methods were employed (Lewis et al., 2006) and have been described in detail previously (Burton et al., 2009).”
Self-citationAntibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
Yuan, X., Wang, Z., Zhang, L., Sui, R., & Khan, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.05.041 · Cited by 22
Metadata
- Authors
- Lewis, H., Beher, D., Cookson, N., Oakley, A., Piggott, M., Morris, C. M., Jaros, E., Perry, R., Ince, P., Kenny, R. A., Ballard, C. G., Shearman, M. S., & Kalaria, R. N.
- Venue
- Neuropathology and Applied Neurobiology
- Publisher
- Wiley
- Published
- 2006-03-13
- Volume
- 32
- Issue
- 2
- Pages
- 103-118
- ISSN
- 0305-1846 (ISSN-L)
- 1365-2990
- OpenAlex
- W2161420960
- Cited by
- 144
- References
- 21
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.